Javier David Benitez Fuentes

Medical Oncologist treating lung 🫁 cancer with a special interest in Global Oncology 🌏, Evidence Synthesis 📖 and Clinical Research 🧐

[Javier David Benitez Fuentes @JavierDavidBen2]

🆕 New paper (SEOM Social Determinants WG): National survey of Spanish oncology professionals (n=258), >80% report SDOH influence cancer development/outcomes, ~68% link SDOH to treatment toxicity. Time, resources, protocols, and training remain barriers. https://t.co/VPZIQUPQ05

[Bishal Gyawali, MD, PhD, FASCO @oncology_bg]

Wondering what to do this weekend? Listen to our podcast!

Many of you may not know that we @OncologyBGLab have recently launched a podcast series called Grounded in Groundshot. We have 5 episodes so far with some legendary names in oncology.

I promise you that our podcasts are not boring! Yet, they are highly educational (I hope).

https://t.co/MBJ4igZ3P3

[JCO Global Oncology @JCOGO_ASCO]

Our Impact Factor is 3.8! Thank you to our incredible community of authors, reviewers, and readers. Together, we are translating authoritative science into better outcomes for cancer patients worldwide.

Submit: https://t.co/Cr7mxixOQ2

[Common Sense Oncology @csoncol]

Ya disponible en YouTube: Escuche a especialistas en oncología analizar el enfoque de Common Sense Oncology en distintos países iberoamericanos y debatir los principales retos y oportunidades para la oncología global.

Véalo aquí: https://t.co/i7WU9FygWp

@GOCCHI #CommonSenseOncology #CáncerDePulmón #Oncología #AtenciónOncológica #OncologíaGlobal @DrRodrigoLastra

[Common Sense Oncology @csoncol]

¡Gracias a todos los que participaron en el webinar de hoy sobre "Common Sense Oncology" en contexto iberoamericano! Si te lo perdiste, la grabación estará disponible pronto en nuestro canal de YouTube. ¡No te la pierdas!

#CommonSenseOncology #CancerDePulmón #Oncología #CancerCare #GlobalOncology

[Bishal Gyawali, MD, PhD, FASCO @oncology_bg]

I’m very much looking forward to speaking at Best of ASCO Vancouver this Friday on a special session on global oncology. Thank you @GillSharlene for the kind invitation. See you all virtually Friday. https://t.co/QXMOC8ykCV

[Javier David Benitez Fuentes @JavierDavidBen2]

@JackWestMD @japan_nobunaga What city?

[Rodrigo Lastra del Prado @DrRodrigoLastra]

Tomorrow!!

[Ginés Luengo Gil 🇩🇰 🇪🇸 @LuengoGil]

Os comparto nuestra última publicación en cáncer renal:

Immunotherapy in Bellini Duct Carcinoma: A Systematic Review

Una colaboración entre hospitales de Alicante, #Cartagena, Murcia y París.

https://t.co/OetSjdULEv

@IMIB_RMurcia @UCAM @Area2Cartagena.

[RioOncology @RIO_Oncology]

Thanks to @csoncol , @ICO_oncologia, @BrunetJbrunet and @darioT_ for this colaboration

[Bishal Gyawali, MD, PhD, FASCO @oncology_bg]

I absolutely love this episode because as you can see, this is as natural as it can get. Two friends start to have a conversation, gets joined by the third friend, and they joke around, tease each other, but also love and respect each other- together leading to a friendly, natural conversation covering some really important topics. Despite our lack of hair, I hope the young generation can relate to us and our conversations and derive some lessons helpful to their own career.

https://t.co/KbTs4Mevr8

[Bishal Gyawali, MD, PhD, FASCO @oncology_bg]

This is the first Adult-only R-rated podcast video I’ve ever recorded 😂

https://t.co/5yhzqVIYob

[BG Lab @OncologyBGLab]

Register today. @oncology_bg and @lateuwen from BG Lab will be there!

[Uğur Özkerim @UOzkerim]

Can we revisit immunotherapy after progression on first-line chemoimmunotherapy in ES-SCLC? 🤔

In this real-world study (n=151), ICI rechallenge was associated with:

✅ Higher ORR (26% vs 11.8%)
✅ Better disease control (75% vs 47.1%)
✅ Longer PFS2 (4.0 vs 2.4 months)
✅ Longer OS (9.4 vs 6.2 months)

While prospective validation is still needed, these data suggest that selected patients who initially benefited from immunotherapy may still derive benefit from an ICI-based approach beyond progression
@OncoAlert @StephenVLiu @GlopesMd @weoncologists @ManuelDomine @christine_lovly @OncoReporte @MedwatchKate @LungCancerEu

[Santiago @umsadiza]

+15.000 muertes/año asociadas a largas esperas en Urgencias en el NHS. La saturación mata. Esperar horas por una cama no es un problema de Urgencias, sino del sistema. Los urgenciólogos no podemos seguir compensando con esfuerzo lo que falta en planificación.

[Yago Garitaonaindía @YGaritaonaindia]

🔵 New in @NatureMedicine: vaping after quitting raises lung cancer risk (Korean cohort, 4.5M)

☣️Risk vs complete quitters:
• Incidence aHR 1.56 (1.24–1.97)
• LC death aHR 2.00 (1.28–3.15)

For clinicians: go for complete cessation, not a switch to e-cigs!!

🔗https://t.co/DlDTvCG3Ep

#LCSM #TobaccoControl

[BG Lab @OncologyBGLab]

Our title says it all:
RECITE this mantra in chemotherapy-induced thrombocytopenia: treat patients, not platelets. @NatRevClinOncol

https://t.co/1C6O331Vct @JavierDavidBen2 @lateuwen @oncology_bg

[OncoDaily @oncodaily]

New Article on Europe’s Oncology Industrial Complex - Rodrigo Lastra del Prado

@DrRodrigoLastra @JavierDavidBen2 @darioT_

https://t.co/17dN2SP9FH

[OncoDaily @oncodaily]

@DrRodrigoLastra @JavierDavidBen2 @darioT_ We would like to inform you that your post has been published on OncoDaily. Thank you for sharing.
https://t.co/17dN2SP9FH

[Javier David Benitez Fuentes @JavierDavidBen2]

@foxpaws_onco @oncology_bg @NatRevClinOncol @OncologyBGLab @lateuwen 😆😆😆 never ending surrogate

[Dr. Foxpaws Fauxpas @foxpaws_onco]

@oncology_bg @NatRevClinOncol @OncologyBGLab @JavierDavidBen2 @lateuwen Can we call it a surrogate for a surrogate for a surrogate marker? 😄

(Plt count > Rx intensity > rx response > survival outcomes)